ReNeuron Group PLC (LON:RENE) said there has been a delay to the Phase 2a clinical evaluation of its treatment for retinitis pigmentosa, an inherited degenerative eye disease.
The company has increased the number of active enrolling sites worldwide to four with the latest patient undergoing a surgical procedure last week to implant the hRPC drug product.
Five days following surgery, the patient got an infection in the treated eye and received antibiotics after which there was a clinical improvement that has continued following additional anti-inflammatory treatment.
As the origin of the infection is not yet clear, ReNeuron said it has temporarily halted dosing further patients until it finds the cause.
This delay will mean three-month data from the extension segment of the Phase 2a study becoming available in the fourth quarter of this year, rather than third.